Skip to main content

Function

May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Plays a role in embryonic stem cells proliferation and differentiation. Up-regulates the expression of FABP5, MYC and cyclins A and E.

Involvement in disease

Diarrhea 5, with tufting enteropathy, congenital

DIAR5

An intractable diarrhea of infancy characterized by villous atrophy and absence of inflammation, with intestinal epithelial cell dysplasia manifesting as focal epithelial tufts in the duodenum and jejunum.

None

The disease is caused by variants affecting the gene represented in this entry.

Lynch syndrome 8

LYNCH8

A form of Lynch syndrome, an autosomal dominant disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. Lynch syndrome is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, it is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical Lynch syndrome is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected Lynch syndrome' or 'incomplete Lynch syndrome' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected.

None

The disease is caused by variants affecting the gene represented in this entry. LYNCH8 results from heterozygous deletion of 3-prime exons of EPCAM and intergenic regions directly upstream of MSH2, resulting in transcriptional read-through and epigenetic silencing of MSH2 in tissues expressing EPCAM.

Post-translational modifications

Hyperglycosylated in carcinoma tissue as compared with autologous normal epithelia. Glycosylation at Asn-198 is crucial for protein stability.

Sequence similarities

Belongs to the EPCAM family.

Tissue specificity

Highly and selectively expressed by undifferentiated rather than differentiated embryonic stem cells (ESC). Levels rapidly diminish as soon as ESC's differentiate (at protein levels). Expressed in almost all epithelial cell membranes but not on mesodermal or neural cell membranes. Found on the surface of adenocarcinoma.

Cellular localization

  • Lateral cell membrane
  • Single-pass type I membrane protein
  • Cell junction
  • Tight junction
  • Colocalizes with CLDN7 at the lateral cell membrane and tight junction.

Alternative names

CD326, GA733-2, M1S2, M4S1, MIC18, TACSTD1, TROP1, EPCAM, Epithelial cell adhesion molecule, Ep-CAM, Adenocarcinoma-associated antigen, Cell surface glycoprotein Trop-1, Epithelial cell surface antigen, Epithelial glycoprotein, Epithelial glycoprotein 314, KS 1/4 antigen, KSA, Major gastrointestinal tumor-associated protein GA733-2, Tumor-associated calcium signal transducer 1, EGP, EGP314, hEGP314

Target type

Proteins

Primary research area

Oncology

Other research areas

  • Immuno-oncology

Molecular weight

34932Da

We found 67 products in 5 categories

Assay Kits

Target

Reactive species

Detection method

Proteins & Peptides

Target

Species of origin

Cell Lines & Lysates

Target

Cell type

Species or organism

Search our catalogue for 'EPCAM' (67)

Products

ab223582

Anti-EpCAM antibody [EPR20532-225]

Recombinant
RabMAb
Advanced Validation
KO Validated
20ul selling size

ab213500

Anti-EpCAM antibody [EPR20532-222]

Recombinant
RabMAb
KO Validated
20ul selling size

ab32392

Anti-EpCAM antibody [E144]

Recombinant
RabMAb
KO Validated
20ul selling size

ab282457

Anti-EpCAM antibody [RM1016]

Recombinant
RabMAb
20ul selling size

ab85987

Anti-EpCAM antibody [323/A3]

KO Validated

ab308057

Anti-EpCAM antibody [AUA1]

Recombinant
20ul selling size

ab225894

Anti-EpCAM antibody [EPR20532-225] - BSA and Azide free

Recombinant
RabMAb
Advanced Validation
KO Validated

ab187372

Anti-EpCAM antibody [VU-1D9]

Recombinant
20ul selling size

ab124825

Anti-EpCAM antibody [EPR677(2)]

Recombinant
RabMAb
20ul selling size

ab232539

Anti-EpCAM antibody [EPR20532-222] - BSA and Azide free

Recombinant
RabMAb
KO Validated

ab261902

Human EPCAM knockout A-431 cell line

Advanced Validation